海特生物
(300683)
| 流通市值：32.66亿 | | | 总市值：34.99亿 |
| 流通股本：1.22亿 | | | 总股本：1.31亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 225,517,028.5 | 159,045,546.74 | 541,449,755.17 | 421,899,722.43 |
| 营业总成本 | 306,332,007.54 | 178,197,247.74 | 673,434,496.86 | 513,069,856.75 |
| 其他经营收益 | | | | |
| 营业利润 | -83,120,683.31 | -26,173,339.62 | -234,104,331.32 | -168,576,906.17 |
| 利润总额 | -87,230,572.41 | -26,833,501.52 | -238,763,512.64 | -171,870,200.97 |
| 净利润 | -79,888,350.24 | -23,933,160.52 | -235,430,201.19 | -160,882,441.08 |
| 每股收益 | | | | |
| 其他综合收益 | - | - | - | - |
| 综合收益总额 | -79,888,350.24 | -23,933,160.52 | -235,430,201.19 | -160,882,441.08 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 1,230,986,872.05 | 1,238,100,955.12 | 1,229,864,966.61 | 1,128,734,835.07 |
| 非流动资产: | | | | |
| 非流动资产合计 | 1,240,281,048.15 | 1,306,633,560.11 | 1,346,677,663.54 | 1,508,246,364.25 |
| 资产总计 | 2,471,267,920.2 | 2,544,734,515.23 | 2,576,542,630.15 | 2,636,981,199.32 |
| 流动负债: | | | | |
| 流动负债合计 | 282,042,329.51 | 297,260,329.7 | 308,845,172.74 | 245,491,526.07 |
| 非流动负债: | | | | |
| 非流动负债合计 | 99,262,193.65 | 101,703,233.57 | 98,297,968.93 | 147,593,664.57 |
| 负债合计 | 381,304,523.16 | 398,963,563.27 | 407,143,141.67 | 393,085,190.64 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 2,082,269,794.19 | 2,137,782,978.56 | 2,160,524,622.97 | 2,233,646,446.66 |
| 股东权益合计 | 2,089,963,397.04 | 2,145,770,951.96 | 2,169,399,488.48 | 2,243,896,008.68 |
| 负债和股东权益合计 | 2,471,267,920.2 | 2,544,734,515.23 | 2,576,542,630.15 | 2,636,981,199.32 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 248,191,047.15 | 125,254,919.49 | 531,242,659.98 | 392,529,823.3 |
| 经营活动现金流出小计 | 251,065,757.34 | 127,766,892.67 | 607,780,636.76 | 468,570,156.98 |
| 经营活动产生的现金流量净额 | -2,874,710.19 | -2,511,973.18 | -76,537,976.78 | -76,040,333.68 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 419,172,275.78 | 280,183,985.67 | 1,649,614,813.12 | 909,221,090.88 |
| 投资活动现金流出小计 | 860,302,661.42 | 658,432,192.21 | 1,316,695,540.45 | 1,061,139,148.22 |
| 投资活动产生的现金流量净额 | -441,130,385.64 | -378,248,206.54 | 332,919,272.67 | -151,918,057.34 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | - | - | 4,000,000 | 4,000,000 |
| 筹资活动现金流出小计 | 6,460,822.06 | 5,173,570.46 | 31,255,922.59 | 25,629,159.58 |
| 筹资活动产生的现金流量净额 | -6,460,822.06 | -5,173,570.46 | -27,255,922.59 | -21,629,159.58 |
| 汇率变动对现金及现金等价物的影响 | -26,073.92 | -14,826.84 | -3,164.26 | 1,699.94 |
| 现金及现金等价物净增加额 | -450,491,991.81 | -385,948,577.02 | 229,122,209.04 | -249,585,850.66 |
| 期末现金及现金等价物余额 | 197,750,577.79 | 262,293,992.58 | 648,242,569.6 | 169,534,509.9 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | -450,491,991.81 | - | 229,122,209.04 | - |